{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:44:46Z","timestamp":1792089886784,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07282-9","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:33:16Z","timestamp":1789482796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Possible CPX-351-associated drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome-like reaction during severe lymphopenia"],"prefix":"10.1007","volume":"105","author":[{"given":"Seiya","family":"Bamba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Hada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Fukutome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"1","key":"7282_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jamadermatol.2023.4450","volume":"160","author":"MC Br\u00fcggen","year":"2024","unstructured":"Br\u00fcggen MC, Walsh S, Ameri MM et al (2024) Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a Delphi-based international consensus. JAMA Dermatol 160(1):37\u201344. https:\/\/doi.org\/10.1001\/jamadermatol.2023.4450","journal-title":"JAMA Dermatol"},{"issue":"1","key":"7282_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2332\/allergolint.55.1","volume":"55","author":"T Shiohara","year":"2006","unstructured":"Shiohara T, Inaoka M, Kano Y (2006) Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 55(1):1\u20138. https:\/\/doi.org\/10.2332\/allergolint.55.1","journal-title":"Allergol Int"},{"issue":"23","key":"7282_CR3","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1056\/NEJMra2204547","volume":"391","author":"D Kroshinsky","year":"2024","unstructured":"Kroshinsky D, Cardones ARG, Blumenthal KG (2024) Drug reaction with eosinophilia and systemic symptoms. N Engl J Med 391(23):2242\u20132254. https:\/\/doi.org\/10.1056\/NEJMra2204547","journal-title":"N Engl J Med"},{"key":"7282_CR4","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.2147\/IJN.S139450","volume":"14","author":"LD Mayer","year":"2019","unstructured":"Mayer LD, Tardi P, Louie AC (2019) CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine 14:3819\u20133830. https:\/\/doi.org\/10.2147\/IJN.S139450","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"7282_CR5","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-18-2990","volume":"25","author":"AC Krauss","year":"2019","unstructured":"Krauss AC, Gao X, Li L et al (2019) FDA approval summary: (Daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin Cancer Res 25(9):2685\u20132690. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2990","journal-title":"Clin Cancer Res"},{"issue":"26","key":"7282_CR6","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE et al (2018) CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 36(26):2684\u20132692. https:\/\/doi.org\/10.1200\/JCO.2017.77.6112","journal-title":"J Clin Oncol"},{"issue":"1","key":"7282_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jaad.2021.01.096","volume":"86","author":"JR Stoll","year":"2022","unstructured":"Stoll JR, Battle L, Moy A et al (2022) Liposomal cytarabine and daunorubicin (CPX-351\/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients. J Am Acad Dermatol 86(1):232\u2013234. https:\/\/doi.org\/10.1016\/j.jaad.2021.01.096","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"7282_CR8","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jaip.2022.02.004","volume":"10","author":"N Hama","year":"2022","unstructured":"Hama N, Abe R, Gibson A, Phillips EJ (2022) Drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. J Allergy Clin Immunol Pract 10(5):1155-1167.e5. https:\/\/doi.org\/10.1016\/j.jaip.2022.02.004","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"7282_CR9","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454\u20132465. https:\/\/doi.org\/10.1182\/blood-2012-03-420489","journal-title":"Blood"},{"key":"7282_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"issue":"2","key":"7282_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1056\/NEJMicm2116076","volume":"387","author":"WK Hung","year":"2022","unstructured":"Hung WK, Chung WH (2022) Drug reaction with eosinophilia and systemic symptoms. N Engl J Med 387(2):167. https:\/\/doi.org\/10.1056\/NEJMicm2116076","journal-title":"N Engl J Med"},{"issue":"4","key":"7282_CR12","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/ccr3.3909","volume":"9","author":"RM Urbantat","year":"2021","unstructured":"Urbantat RM, Popper V, Menschel E et al (2021) CPX-351 (Vyxeos\u00ae) can cause severe rash in acute myeloid leukemia-A case report. Clin Case Rep 9(4):1933\u20131936. https:\/\/doi.org\/10.1002\/ccr3.3909","journal-title":"Clin Case Rep"},{"issue":"11","key":"7282_CR13","doi-asserted-by":"publisher","first-page":"e1015","DOI":"10.1111\/1346-8138.17954","volume":"52","author":"N Asano","year":"2025","unstructured":"Asano N, Okamura K, Yamamoto K, Shimomura Y (2025) Case of CPX-351-induced purpuric rash occurred in a patient with pure erythroid leukemia. J Dermatol 52(11):e1015\u2013e1016. https:\/\/doi.org\/10.1111\/1346-8138.17954","journal-title":"J Dermatol"},{"issue":"1","key":"7282_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/10428194.2025.2568744","volume":"67","author":"FE Palumbo","year":"2026","unstructured":"Palumbo FE, Vetro C, Maugeri C et al (2026) Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351. Leuk Lymphoma 67(1):218\u2013219. https:\/\/doi.org\/10.1080\/10428194.2025.2568744","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"7282_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","volume":"59","author":"JL Bolognia","year":"2008","unstructured":"Bolognia JL, Cooper DL, Glusac EJ (2008) Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 59(3):524\u2013529. https:\/\/doi.org\/10.1016\/j.jaad.2008.05.018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"7282_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","volume":"156","author":"SH Kardaun","year":"2007","unstructured":"Kardaun SH, Sidoroff A, Valeyrie-Allanore L et al (2007) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 156(3):609\u2013611. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07704.x","journal-title":"Br J Dermatol"},{"issue":"5","key":"7282_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","volume":"156","author":"T Shiohara","year":"2007","unstructured":"Shiohara T, Iijima M, Ikezawa Z, Hashimoto K (2007) The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 156(5):1083\u20131084. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07807.x","journal-title":"Br J Dermatol"},{"issue":"3","key":"7282_CR18","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jaad.2018.08.052","volume":"80","author":"Y Mizukawa","year":"2019","unstructured":"Mizukawa Y, Hirahara K, Kano Y, Shiohara T (2019) Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol 80(3):670-678.e2. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.052","journal-title":"J Am Acad Dermatol"},{"key":"7282_CR19","doi-asserted-by":"publisher","first-page":"1187937","DOI":"10.3389\/fmed.2023.1187937","volume":"10","author":"CB Chen","year":"2023","unstructured":"Chen CB, Hung WK, Wang CW et al (2023) Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review. Front Med (Lausanne) 10:1187937. https:\/\/doi.org\/10.3389\/fmed.2023.1187937","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"7282_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","volume":"69","author":"K Ogawa","year":"2013","unstructured":"Ogawa K, Morito H, Hasegawa A et al (2013) Identification of thymus and activation-regulated chemokine (TARC\/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)\/drug rash with eosinophilia and systemic symptoms (DRESS). J Dermatol Sci 69(1):38\u201343. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.10.002","journal-title":"J Dermatol Sci"},{"key":"7282_CR21","doi-asserted-by":"publisher","first-page":"1118527","DOI":"10.3389\/fmed.2023.1118527","volume":"10","author":"T Chimbetete","year":"2023","unstructured":"Chimbetete T, Choshi P, Pedretti S et al (2023) Skin infiltrating T-cell profile of drug reaction with eosinophilia and systemic symptoms (DRESS) reactions among HIV-infected patients. Front Med (Lausanne) 10:1118527. https:\/\/doi.org\/10.3389\/fmed.2023.1118527","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"7282_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5114\/ada.2018.75249","volume":"35","author":"M Albanesi","year":"2018","unstructured":"Albanesi M, Carluccio P, Nico A et al (2018) A desensitization protocol for delayed allergy to cytarabine: analysis of two cases. Postepy Dermatol Alergol 35(2):222\u2013224. https:\/\/doi.org\/10.5114\/ada.2018.75249","journal-title":"Postepy Dermatol Alergol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07282-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07282-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:45:01Z","timestamp":1792086301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07282-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7282"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07282-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"4 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board and Ethics Committee of Kyoto University (R1085) and was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of the clinical details and images included in this report was obtained from the patient.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"457"}}